Cargando…
Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876277/ http://dx.doi.org/10.1186/1897-4287-8-S1-O5 |
| _version_ | 1782181690394804224 |
|---|---|
| author | Burn, John Mathers, John C Gerdes, Anne-Marie Bisgaard, MarieLuise Evans, Gareth Eccles, Diana Lindblom, Annika Macrae, Findlay Maher, Eamonn R Mecklin, Jukka-Pekka Moslein, Gabriela Olschwang, Sylviane Ramesar, Raj Vasen, Hans FA Wijnen, Juul Barker, Gail Elliott, Faye Lynch, Henry Bishop, D Tim |
| author_facet | Burn, John Mathers, John C Gerdes, Anne-Marie Bisgaard, MarieLuise Evans, Gareth Eccles, Diana Lindblom, Annika Macrae, Findlay Maher, Eamonn R Mecklin, Jukka-Pekka Moslein, Gabriela Olschwang, Sylviane Ramesar, Raj Vasen, Hans FA Wijnen, Juul Barker, Gail Elliott, Faye Lynch, Henry Bishop, D Tim |
| author_sort | Burn, John |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2876277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-28762772010-05-27 Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy Burn, John Mathers, John C Gerdes, Anne-Marie Bisgaard, MarieLuise Evans, Gareth Eccles, Diana Lindblom, Annika Macrae, Findlay Maher, Eamonn R Mecklin, Jukka-Pekka Moslein, Gabriela Olschwang, Sylviane Ramesar, Raj Vasen, Hans FA Wijnen, Juul Barker, Gail Elliott, Faye Lynch, Henry Bishop, D Tim Hered Cancer Clin Pract Oral Presentation BioMed Central 2010-05-25 /pmc/articles/PMC2876277/ http://dx.doi.org/10.1186/1897-4287-8-S1-O5 Text en Copyright ©2010 Burn et al; licensee BioMed Central Ltd. |
| spellingShingle | Oral Presentation Burn, John Mathers, John C Gerdes, Anne-Marie Bisgaard, MarieLuise Evans, Gareth Eccles, Diana Lindblom, Annika Macrae, Findlay Maher, Eamonn R Mecklin, Jukka-Pekka Moslein, Gabriela Olschwang, Sylviane Ramesar, Raj Vasen, Hans FA Wijnen, Juul Barker, Gail Elliott, Faye Lynch, Henry Bishop, D Tim Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title_full | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title_fullStr | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title_full_unstemmed | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title_short | Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy |
| title_sort | cancer occurrence during follow-up of the capp2 study -aspirin use for up to four years significantly reduces lynch syndrome cancers for up to several years after completion of therapy |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876277/ http://dx.doi.org/10.1186/1897-4287-8-S1-O5 |
| work_keys_str_mv | AT burnjohn canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT mathersjohnc canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT gerdesannemarie canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT bisgaardmarieluise canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT evansgareth canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT ecclesdiana canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT lindblomannika canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT macraefindlay canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT mahereamonnr canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT mecklinjukkapekka canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT mosleingabriela canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT olschwangsylviane canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT ramesarraj canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT vasenhansfa canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT wijnenjuul canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT barkergail canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT elliottfaye canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT lynchhenry canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT bishopdtim canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy AT canceroccurrenceduringfollowupofthecapp2studyaspirinuseforuptofouryearssignificantlyreduceslynchsyndromecancersforuptoseveralyearsaftercompletionoftherapy |